Insider trade

Dexcom (DXCM): CEO sold ~$2.29M

Kevin R Sayer, CEO at Dexcom, sold ~$2.29M of Dexcom shares.

~$2.29M
Approx. value · 32K sh @ $70.38
372K
Holds after · shares reported
Traded
Mar 12, 2025
Filed
Mar 14, 2025

What stands out in this filing

  • The sale was 8.0% of the shares this insider held before it; the filing reports 372,029 shares afterwards.
  • 32,498 shares at an average of $70.38 each, as reported on the form.
  • Footnote references tax withholding.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 31, 2024CongressDisclosed sale of DXCM — reported range $50,001 - $100,000
  2. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REF: STK-OR-001
  3. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REFs: STK-OM-001, STR-OM-001, STR-OR-001
  4. Jan 27, 2025FDARecall: Dexcom G6, Continuous Glucose Monitoring System, REF: STK-OE-001
  5. Jan 29, 2025Insider · 5 peopleInsiders: 5 sales (~$3.6M)
  6. Feb 25, 2025CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
  7. Mar 10, 2025Insider · 1 personInsiders: 3 sales (~$517K)
  8. Mar 12, 2025 · this disclosureInsiderCEO sold ~$2.29M of DXCM shares in the open market

What came next

  1. Mar 12, 2025Insider · 4 peopleInsiders: 4 sales (~$3.5M)
  2. Mar 17, 2025InsiderDirector sold ~$25K of DXCM shares in the open market
  3. Apr 7, 2025CongressDisclosed sale of DXCM — reported range $15,001 - $50,000
  4. Apr 8, 2025CongressDisclosed sale of DXCM — reported range $1,001 - $15,000
  5. Apr 9, 2025FDAFDA device clearance: Dexcom G7 15 Day Continuous Glucose Monitoring System
  6. May 5, 2025FDARecall: Dexcom G7 iOS Application, Ref: SW12300 used in conjunction with the Dexcom G7 Continuous Glucose Monitoring (CGM) system
  7. May 8, 2025CongressDisclosed purchase of DXCM — reported range $15,001 - $50,000
  8. May 12, 2025FDARecall: Dexcom One+ Continuous Glucose Monitoring System, SKU(Part Number): STK-D7-013 (MT28285-1), STK-D7-014 (MT28285-1), STK-D7-103 (MT28285-2)
  9. May 12, 2025FDARecall: Dexcom One Continuous Glucose Monitoring System, SKUs(Part Number): STK-DO-006 (MT27409-1), STK-DO-013 (MT27409-1), STK-DO-103 (MT27409-2), STK-DO-109 (MT27409…
  10. May 12, 2025FDARecall: Dexcom G6 Glucose Receiver, SKUs (Part Number): STK-FM-001 (MT27408-1) & STK-FR-001 (MT27408-1)
  11. May 12, 2025FDARecall: Dexcom G7 Glucose Receiver, SKUs (part number): STK-AT-011(MT26403-0), STK-AT-012 (MT26403-0), STK-AT-013 (MT26403-0), STK-GT-001 (MT26403-1), STK-GT-008 (MT26…
  12. May 12, 2025CongressDisclosed sale of DXCM — reported range $15,001 - $50,000
  13. May 15, 2025CongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
  14. May 23, 2025InsiderOfficer sold ~$843K of DXCM shares in the open market
  15. May 27, 2025InsiderOfficer sold ~$526K of DXCM shares in the open market
  16. Jun 13, 2025InsiderDirector sold ~$214K of DXCM shares in the open market
  17. Jun 16, 2025Insider · 3 peopleInsiders: 3 sales (~$574K)
  18. Jun 26, 2025InsiderOfficer sold ~$125K of DXCM shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Kevin R Sayer, Chairman, CEO & President

The full history of Kevin R Sayer, Chairman, CEO & President is on the profile page.

How this filing works

Explore the data

Common questions

Which Dexcom (DXCM) insider traded, and how much?

Kevin R Sayer, CEO at Dexcom, sold ~$2.29M of Dexcom shares. 32K shares at $70.38.

When did it happen, and when was it made public?

Traded: Mar 12, 2025. Filed: Mar 14, 2025. That is 2 days between the two dates.

What stands out in this filing?

The sale was 8.0% of the shares this insider held before it; the filing reports 372,029 shares afterwards. 32,498 shares at an average of $70.38 each, as reported on the form. Footnote references tax withholding.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Dexcom recently?

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.

Does this mean DXCM stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Dexcom

Everything OQRO holds on this company is on its DXCM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data